 -Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-BRIDGEWATER, N.J., Aug. 06, 2020 GLOBE NEWSWIRE -- Osmotica Pharmaceuticals plc Nasdaq: OSMT Osmotica or the Company, a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 second quarter financial results on Tuesday, August 11, 2020, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James JD Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: Date Tuesday, August 11, 2020 Time 4:30 p.m. ET Toll free U.S. 866 672-5029 International 409 217-8312 Conference ID 5287688 Webcast live and replay under the Investor News section About Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of four promoted products and approximately 30 non-promoted products, several of which incorporate Osmoticas proprietary Osmodex drug delivery system. RVL Pharmaceuticals, Inc. is the Companys ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the Companys non-promoted products, including complex generic formulations.Osmotica has operations in the United States, Argentina, and Hungary.Investor and Media Relations for Osmotica Pharmaceuticals plc Lisa M. Wilson In-Site Communications, Inc. T: 212-452-2793 E: 